latest news releases from the newsroom
MEDirect Latino, Inc.
MEDirect Latino Inc. Exceeds One Million Dollars in March Revenues
PLANTATION, Fla., April 11, 2006 (PRIMEZONE) -- MEDirect Latino Inc. (Pink Sheets:MLTO) (www.medirectlatino.org), the first national provider of direct-to-consumer Medicare reimbursed medical products focused exclusively on chronic diseases afflicting the Hispanic community, today announced record results for March 2006 in gross billings and new patient shipments. MEDirect Latino reports gross billings of $1,002,391 during the month, a 10.52% increase over February's billings of $906,936. The Company's gross product profit margins remained unchanged at 78%. Total new patient shipments for March numbered 4,421, an increase of 20.39% over February's shipments of 3,672. The Company's 'patient hold journal' (approved and pending shipment for regulatory processing), closed the month with 5,203 additional customer orders, an increase of 17% over February's 4,447 patient hold journal. MEDirect Latino expects to monetize its approved and pending patient orders in April, which is typical to the Company's model.
VioQuest Pharmaceuticals Discusses Targeted Therapeutics For Cancer on News 12 New Jersey
BASKING RIDGE, N.J., April 11, 2006 (PRIMEZONE) -- Pamela Harris, M.D., Chief Medical Officer and Dick Welter, Ph.D., Vice President of Corporate Business Development of VioQuest Pharmaceuticals (OTCBB:VQPH), discussed the emerging paradigm of personalized medicine during a taped interview which was aired by "12 to Your Health," a popular health show produced by New Jersey's News 12. Drs. Welter and Harris described how the advances in molecular biology have made it possible for physicians to profile the cancer-promoting steps in each patient's tumor and for pharmaceutical companies to develop treatments that "target" these steps. This kind of approach allows patients to get the best therapy for their particular cancer while not being exposed unnecessarily to toxic medications with little potential of helping them. The entire field of targeted therapeutics has already revolutionized and is likely to dominate cancer treatment for the foreseeable future. As Drs. Harris and Welter explained, VioQuest Pharmaceuticals is on the cutting edge of developing these targeted therapeutics.
Occidental Petroleum Corp.
Occidental to Hold Earnings Conference Call
LOS ANGELES, April 11, 2006 (PRIMEZONE) -- Occidental Petroleum Corporation (NYSE:OXY) will hold a conference call on Tuesday, April 25, 2006, following the release of its first-quarter 2006 financial results. The conference call, which will begin at 11:30 a.m. EST, may be accessed by calling 1-888-873-8496. The conference call also can be heard live on the company's website, www.oxy.com.
Power Technology Inc.
Power Technology Signs Definitive Agreement to Acquire Sentry Power
HOUSTON, April 11, 2006 (PRIMEZONE) -- Alternative energy company Power Technology, Inc. (OTCBB:PWTC) announced today that it has signed definitive documents to acquire the assets of Sentry Power LLC (http://www.sentrypowersystems.com) for a total consideration of $1,195,000 paid $960,000 in common stock of Power Technology and $235,000 in assumed debt. Sentry Power sells battery driven back up uninterrupted power supply systems for commercial and residential usage. The agreement is binding and subject only to the completion of customary due diligence and an audit of the Sentry Power's previous operations.